A significant rise in respiratory syncytial virus (RSV) cases is pushing hospitals to their limits while new vaccines offer hope for both the very young and old. RSV remains the leading cause of hospitalization among United States infants. The virus poses a particular threat to two key groups: infants under 8 months and adults over 75. A new vaccine, nirsevimab, has shown promising results in protecting both populations. Phase 3 trial data showed that nirsevimab cut RSV hospitalizations in healthy full-term and near-full-term infants by 77%. “This winter is shaping up to be another worrying one for many older people,” … Continue reading RSV Hospitalizations Surge; New Vaccine Cuts Infant Cases by 77%